Experts in the life sciences industry are expressing concerns about the challenges posed by the EU AI Act as the sector adapts to new regulations. While the Act aims to protect citizens, it may complicate the integration of AI technologies into drug development processes.
Boomi CEO Steve Lucas emphasizes the necessity of a governance plan for AI agents, stating that without it, organizations are destined to fail. He highlights the shift from deterministic processes to agentic processes in technology, urging the importance of human oversight in AI decision-making.
Take the first steps in your transformation towards international AI compliance.
Our expert sales team is here to answer your questions, just leave your email and we’ll get in touch.
